$ABT News

Abbott Laboratories (NYSE:ABT): A Strong Candidate for Quality Investors

Abbott starts TriClip study amid rising competition for heart valve repair

UBS Maintains Buy on Abbott Laboratories, Lowers Price Target to $125

Abbott Rides Key Diabetes, Oncology and Heart Care Innovation Trends

Abbott (ABT) Lands Exclusive Rights To FDA Approved Blood Based CRC Test

Abbott (ABT) Raised Its Profit Forecast. What’s Driving Its Growth?

Freenome secures FDA nod for blood-based colorectal cancer test

Abbott Laboratories (ABT) Fell as Guidance and Litigation Concerns Overshadowed Growth

Is Abbott Stock Attractive After Its Earnings and Guidance Update?

FDA Approves Freenome’s SimpleScreen™ CRC Blood-Based Screening Test; Abbott to Commercialize in the U.S.

ISRG vs. ABT: Which MedTech Giant Is the Smarter Investment Now?

Abbott Laboratories (ABT) Earnings Drew Fresh Attention, Is It Still Below Fair Value?

Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know

This Dividend King Could Be One of the Safest Stocks to Own Right Now

Abbott Laboratories Seen on Track for H2 Growth Acceleration, RBC Says

Citigroup Maintains Buy on Abbott Laboratories, Raises Price Target to $112

Piper Sandler Reiterates Overweight on Abbott Laboratories, Raises Price Target to $118

ABT Q2 Earnings Call Flags Stronger Second-Half Setup

Abbott discloses cyberattack on cancer diagnostics business

JP Morgan Maintains Overweight on Abbott Laboratories, Raises Price Target to $120